Out of 2,000 children studied as part of the clinical trials, there were no cases of COVID-19 from seven days after dose two.


Pfizer jab approved for 12 to 15-year-olds by Medicines and Healthcare products Regulatory Agency


Pfizer jab approved for 12 to 15-year-olds by Medicines and Healthcare products Regulatory Agency

London::

 

The UK’s medicines regulator has approved the Pfizer/BioNTech coronavirus vaccine for 12 to 15-year-olds.

The Medicines and Healthcare products Regulatory Agency (MHRA) said the decision followed a “rigorous review” of safety and effectiveness in that age group – and that the benefits of having the COVID jab outweighed the risks.

Dr June Raine, MHRA chief executive, said: “We have in place a comprehensive safety surveillance strategy for monitoring the safety of all UK-approved COVID-19 vaccines and this surveillance will include the 12- to 15-year age group.”

A Department of Health and Social Care spokesperson said the next step was for the Joint Committee on Vaccination and Immunisation (JCVI) to advise whether routine vaccination should be offered to those aged 12 to 17.

“We will be guided by the expert advisors and will update in due course.”

The Pfizer/BioNTech jab was approved for use in the UK for 16 and 17-year-olds in December 2020.

The JCVI’s current advice is that those aged 16-18 should be offered vaccination if they are in a priority Phase 1 group or are the household contacts of immunosuppressed people.

There is no routine vaccination of under 18s currently underway.

More than 2,000 children were involved in the clinical trial to determine the safety of the Pfizer/BioNTech vaccine, the chairman of the Commission on Human Medicines said.

Professor Sir Munir Pirmohamed said that the vaccine’s benefits “do outweigh any risk” based on the data.

He added out of the 2,000 children studied as part of the randomised, placebo-controlled clinical trials, there were no cases of COVID-19 from seven days after the second dose, compared with 16 cases in the placebo group.

In addition, data on neutralising antibodies showed the vaccine working at the same level as seen in adults aged 16-25 years.

“These are extremely positive results,” he said.

Leave a Reply

Your email address will not be published. Required fields are marked *





related stories


error: Content is protected !!